Compare THAR & CHPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THAR | CHPG |
|---|---|---|
| Founded | 2017 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.8M | 101.5M |
| IPO Year | 2022 | N/A |
| Metric | THAR | CHPG |
|---|---|---|
| Price | $2.87 | $10.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 565.1K | 3.5K |
| Earning Date | 11-12-2025 | 07-23-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $262.78 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $9.81 |
| 52 Week High | $9.08 | $10.24 |
| Indicator | THAR | CHPG |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | N/A |
| Support Level | $2.77 | N/A |
| Resistance Level | $3.56 | N/A |
| Average True Range (ATR) | 0.25 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 41.53 | 0.00 |
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Championsgate Acquisition Corp is a blank check company.